Transthyretin amyloidosis (ATTR) is caused by the misfolding and aggregation of the transthyretin (TTR) protein, leading to multi-organ damage. Two main forms exist: hereditary ATTR (ATTRv), linked to ...
Earlier in May 2026, Alnylam Pharmaceuticals reported new HELIOS-B Phase 3 analyses showing its TTR silencer vutrisiran delivered durable transthyretin knockdown, consistent clinical benefit across ...
Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches an ...
The presence of genetic variants that affect the stabilization of the tetrameric protein transthyretin (TTR) is associated with both all-cause and cardiovascular mortality, according to new data from ...
Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state stabilizers are promising ...
Approximately 4% of black Americans carry a valine-to-isoleucine substitution (V122I) in the transthyretin protein, which has been associated with late-onset restrictive amyloid cardiomyopathy and ...
Researchers reveal the impact of transthyretin protein levels on heart disease risk. Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine have ...
Transthyretin can aggregate into fibrils and get deposited in the nervous system (neuropathy) and heart (cardiomyopathy). This is called transthyretin amyloidosis. Depending on whether the disease is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results